Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Aref Al‐Kali, H. Joachim Deeg, Prapti A. Patel, Mitchell Sabloff, Mary‐Margaret Keating, Nancy Zhu, Nashat Gabrail, Salman Fazal, Joseph Maly, Olatoyosi Odenike, Hagop Kantarjian, Amy E. DeZern, Casey L. O’Connell, Gail J. Roboz, Lambert Busque, Rena Buckstein, Harshad Amin, Jasleen K. Randhawa, Brian Leber, Aditi Shastri, Kim‐Hien Dao, Aram Oganesian, Yong Hao, Harold Keer, Mohammad Azab, Michael R. Savona